Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

OSE Immunotherapeutics Announces 1st Peer-Reviewed Publication in “Science Advances” on OSE-230

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the first peer-reviewed publication on OSE-230, a novel and innovative approach in the management of the resolution of chronic and severe inflammation, in Science Advances.

The article, entitled: “Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution  reports on the discovery and preclinical data for OSE-230, an innovative agonist antibody against ChemR23, also known as chemerin chemokine-like receptor 1 (CMKLR1), a G-protein coupled receptor (GPCR) expressed on myeloid immune cells known to modulate inflammation.

OSE Immunotherapeutics’ R&D team identified ChemR23 as a GPCR receptor of the resolution program overexpressed in the inflamed tissues of patients unresponsive to anti-TNFα or anti-α4β7 therapies with high unmet medical needs.

The preclinical results demonstrate that OSE-230 accelerates inflammation resolution and tissue hemostasis in severe inflammatory models. Most importantly, OSE-230 triggers pro-resolutive actions resulting in the resolution of chronic inflammation in models where such recovery is deficient or missing. The direct consequence of OSE-230 pro-resolutive actions is a marked reduction of fibrosis in inflamed tissues and a significant reduction in the development of inflammation-driven tumors.

Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics, comments: “We are very pleased with this publication on OSE-230 in ‘Science Advances’, a journal of highest scientific level which recognizes the disruptive innovation of our research program. This is the first peer-reviewed publication to describe an agonist monoclonal antibody, which triggers pro-resolutive mechanisms in macrophages and neutrophils in chronic inflammatory condition. This breakthrough discovery opens the development pathway of OSE-230 in various chronic inflammations such as inflammatory bowel diseases, arthritis, type 1 diabetes, lung or kidney inflammatory diseases. We believe this discovery suggests OSE-230 could also be used as a treatment in severe COVID-19 patients where excessive inflammation has a key role in the physiopathology of the disease”.

Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, adds: “OSE-230 is an additional program that positions OSE as a true leader in innovation and discovery of new pathways. Based on the strong potential of OSE-230, we look forward to initiating an ambitious development plan to address the numerous patients’ need for disruptive innovations to manage complex inflammatory diseases.”

This research was the result of a productive collaboration between the OSE R&D team and scientific partners at Ambiotis, a French Contract Research Organization specialized in the active resolution of inflammation, MAbSilico, a deep technology innovative French TechBio specialized in Artificial Intelligence and the CRTI (Center for Research in Transplantation and Immunology, UMR1064, INSERM, Nantes University based at the University Hospital of Nantes).

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine